Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 MesoblastAdverum BiotechnologiesTaysha Gene TherapiesCortexymeRubius Therapeutics
SymbolNASDAQ:MESONASDAQ:ADVMNASDAQ:TSHANASDAQ:CRTXNASDAQ:RUBY
Price Information
Current Price$8.45$9.07$25.00$31.88$22.26
52 Week RangeHoldBuyBuyHoldHold
MarketRank™
Overall Score1.41.71.81.31.6
Analysis Score3.23.43.53.11.1
Community Score3.12.43.82.62.3
Dividend Score0.00.00.00.00.0
Ownership Score0.02.50.80.84.2
Earnings & Valuation Score0.60.00.60.00.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyHoldHold
Consensus Price Target$14.55$23.50$41.75$50.00$23.33
% Upside from Price Target72.19% upside159.10% upside67.00% upside56.84% upside4.82% upside
Trade Information
Market Cap$1.10 billion$887.01 million$944.03 million$942.12 million$1.81 billion
Beta3.711.72N/A0.952.37
Average Volume609,205840,77089,785306,0131,746,105
Sales & Book Value
Annual Revenue$32.16 million$250,000.00N/AN/AN/A
Price / Sales34.093,548.04N/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$4.70 per share$2.71 per shareN/A$4.30 per share$3.44 per share
Price / Book1.803.35N/AN/AN/A
Profitability
Net Income$-77,940,000.00$-64,490,000.00N/A$-36,980,000.00$-163,460,000.00
EPS($0.74)($1.01)N/A($1.94)($2.08)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-591.00%N/AN/AN/AN/A
Return on Equity (ROE)-18.69%-32.23%N/A-37.78%-77.33%
Return on Assets (ROA)-13.85%-28.02%N/A-35.24%-49.05%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.10%N/AN/AN/A0.43%
Current Ratio1.32%28.53%24.02%8.71%7.15%
Quick Ratio1.32%28.53%24.02%8.71%7.15%
Ownership Information
Institutional Ownership Percentage2.80%97.41%42.19%55.48%93.74%
Insider Ownership Percentage18.80%12.40%N/A19.80%58.40%
Miscellaneous
Employees1021673837204
Shares Outstanding129.74 million97.80 million37.76 million29.55 million81.23 million
Next Earnings Date5/26/2021 (Estimated)5/27/2021 (Estimated)6/2/2021 (Estimated)5/11/2021 (Estimated)5/10/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Should You Take Comfort From Insider Transactions At Rubius Therapeutics, Inc. (NASDAQ:RUBY)?Should You Take Comfort From Insider Transactions At Rubius Therapeutics, Inc. (NASDAQ:RUBY)?
finance.yahoo.com - April 12 at 5:57 PM
Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the ...Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the ...
apnews.com - April 12 at 12:56 PM
Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive CancersRubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
finance.yahoo.com - April 12 at 12:56 PM
Zacks: Analysts Expect Rubius Therapeutics, Inc. (NASDAQ:RUBY) to Post -$0.54 EPSZacks: Analysts Expect Rubius Therapeutics, Inc. (NASDAQ:RUBY) to Post -$0.54 EPS
americanbankingnews.com - April 10 at 8:08 AM
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial ...Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial ...
apnews.com - April 9 at 12:00 PM
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual MeetingRubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
finance.yahoo.com - April 9 at 12:00 PM
Rubius Therapeutics (NASDAQ:RUBY) Shares Gap Up to $26.50Rubius Therapeutics (NASDAQ:RUBY) Shares Gap Up to $26.50
americanbankingnews.com - April 1 at 12:08 PM
Rubius Therapeutics (NASDAQ:RUBY) Shares Up 9.9%Rubius Therapeutics (NASDAQ:RUBY) Shares Up 9.9%
americanbankingnews.com - March 31 at 12:56 PM
Rubius Therapeutics, Inc. (NASDAQ:RUBY) Stock Forecast: Bullish Sentiment Portends 23.88% Upside in 2021Rubius Therapeutics, Inc. (NASDAQ:RUBY) Stock Forecast: Bullish Sentiment Portends 23.88% Upside in 2021
stocksregister.com - March 29 at 10:10 AM
Rubius Therapeutics Charts A New Path For Hard-To-Treat CancersRubius Therapeutics Charts A New Path For Hard-To-Treat Cancers
finance.yahoo.com - March 27 at 1:25 PM
Rubius Therapeutics (NASDAQ:RUBY) Shares Gap Down to $31.78Rubius Therapeutics (NASDAQ:RUBY) Shares Gap Down to $31.78
americanbankingnews.com - March 26 at 11:40 AM
Investors Take Advantage of 5.78% Gain In Rubius Therapeutics, Inc. (NASDAQ:RUBY)Investors Take Advantage of 5.78% Gain In Rubius Therapeutics, Inc. (NASDAQ:RUBY)
stocksregister.com - March 26 at 5:15 AM
Rubius Therapeutics (NASDAQ:RUBY) Price Target Raised to $40.00 at HC WainwrightRubius Therapeutics (NASDAQ:RUBY) Price Target Raised to $40.00 at HC Wainwright
americanbankingnews.com - March 22 at 10:20 AM
Rubius Therapeutics (NASDAQ:RUBY) PT Raised to $20.00Rubius Therapeutics (NASDAQ:RUBY) PT Raised to $20.00
americanbankingnews.com - March 22 at 10:20 AM
Rubius Therapeutics (NASDAQ:RUBY) Given New $40.00 Price Target at HC WainwrightRubius Therapeutics (NASDAQ:RUBY) Given New $40.00 Price Target at HC Wainwright
marketbeat.com - March 22 at 8:57 AM
First Week of RUBY November 19th Options TradingFirst Week of RUBY November 19th Options Trading
nasdaq.com - March 19 at 7:04 PM
Mid-day market update: Dow gains 100 points; Rubius Therapeutics (RUBY Stock) shares plummetMid-day market update: Dow gains 100 points; Rubius Therapeutics (RUBY Stock) shares plummet
fxstreet.com - March 17 at 1:34 PM
Implied Volatility Surging for Rubius Therapeutics (RUBY) Stock OptionsImplied Volatility Surging for Rubius Therapeutics (RUBY) Stock Options
finance.yahoo.com - March 17 at 1:34 PM
Rubius Therapeutics: Promising Cancer Treatment Data De-Risks PipelineRubius Therapeutics: Promising Cancer Treatment Data De-Risks Pipeline
finance.yahoo.com - March 17 at 8:34 AM
Rubius Therapeutics Prices Upsized Public Offering of Common StockRubius Therapeutics Prices Upsized Public Offering of Common Stock
finance.yahoo.com - March 17 at 12:39 AM
Biotech Stocks To Buy In March 2021? 4 Names To KnowBiotech Stocks To Buy In March 2021? 4 Names To Know
nasdaq.com - March 16 at 2:38 PM
Why Rubius Therapeutics Is Trading Higher TodayWhy Rubius Therapeutics Is Trading Higher Today
msn.com - March 16 at 2:38 PM
Notable Monday Option Activity: LLY, RUBY, PENNNotable Monday Option Activity: LLY, RUBY, PENN
nasdaq.com - March 15 at 6:29 PM
Rubius Therapeutics Stock Trading Higher On Positive Efficacy, Safety RTX-240 Data In Solid Tumor StudyRubius Therapeutics Stock Trading Higher On Positive Efficacy, Safety RTX-240 Data In Solid Tumor Study
finance.yahoo.com - March 15 at 6:29 PM
Why Rubius Therapeutics Stock Is Skyrocketing TodayWhy Rubius Therapeutics Stock Is Skyrocketing Today
fool.com - March 15 at 6:29 PM
Rubius Therapeutics Announces Proposed Public Offering of Common StockRubius Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 15 at 6:29 PM
DateCompanyBrokerageAction
4/7/2021MesoblastMaxim GroupUpgrade
1/19/2021MesoblastJefferies Financial GroupDowngrade
12/15/2020MesoblastHC WainwrightReiterated Rating
12/4/2020MesoblastChardan CapitalDowngrade
10/22/2020MesoblastRoyal Bank of CanadaInitiated Coverage
5/28/2020MesoblastLADENBURG THALM/SH SHBoost Price Target
12/19/2019MesoblastDawson JamesInitiated Coverage
10/22/2019MesoblastCantor FitzgeraldReiterated Rating
9/10/2019MesoblastOppenheimerSet Price Target
12/15/2020Adverum BiotechnologiesUBS GroupInitiated Coverage
11/12/2020Adverum BiotechnologiesRaymond JamesUpgrade
11/5/2020Adverum BiotechnologiesLifesci CapitalReiterated Rating
8/11/2020Adverum BiotechnologiesSVB LeerinkBoost Price Target
8/10/2020Adverum BiotechnologiesPiper SandlerBoost Price Target
5/5/2020Adverum BiotechnologiesSunTrust BanksUpgrade
4/28/2020Adverum BiotechnologiesThe Goldman Sachs GroupInitiated Coverage
1/13/2020Adverum BiotechnologiesPiper Jaffray CompaniesBoost Price Target
3/15/2021Taysha Gene TherapiesMorgan StanleyBoost Price Target
3/1/2021Taysha Gene TherapiesWilliam BlairInitiated Coverage
12/11/2020CortexymeSmith Barney CitigroupInitiated Coverage
12/11/2020CortexymeCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
12/7/2020CortexymeBank of AmericaUpgrade
5/13/2020CortexymeCanaccord GenuityReiterated Rating
6/3/2019CortexymeCredit Suisse GroupInitiated Coverage
6/3/2019CortexymeJMP SecuritiesInitiated Coverage
10/14/2020Rubius TherapeuticsJPMorgan Chase & Co.Initiated Coverage
3/13/2020Rubius TherapeuticsGuggenheimLower Price Target
9/9/2019Rubius TherapeuticsRobert W. BairdInitiated Coverage
(Data available from 4/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.